Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of fungal infections
3.2.1.2 Rising awareness and adoption of antifungal drugs
3.2.1.3 Increasing R&D activities for developing novel antifungal drugs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Increasing antifungal drug resistance
3.2.2.2 Increasing product recalls
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Azoles
5.3 Echinocandins
5.4 Polyenes
5.5 Allylamines
5.6 Other drug classes
Chapter 6 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Dermatophytosis
6.3 Aspergillosis
6.4 Candidiasis
6.5 Mucormycosis
6.6 Other indications
Chapter 7 Market Estimates and Forecast, By Infection Type, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Systemic antifungal infections
7.3 Superficial antifungal infections
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Topical
8.4 Injectable
Chapter 9 Market Estimates and Forecast, By Medication, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Prescription
9.3 OTC
Chapter 10 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 Branded
10.3 Generic
Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
11.1 Key trends
11.2 Hospital pharmacies
11.3 Retail pharmacies
11.4 Online pharmacies
Chapter 12 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
12.1 Key trends
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 France
12.3.4 Spain
12.3.5 Italy
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Australia
12.4.5 Rest of Asia Pacific
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest of Latin America
12.6 Middle East and Africa
12.6.1 South Africa
12.6.2 Saudi Arabia
12.6.3 Rest of Middle East and Africa
Chapter 13 Company Profiles
13.1 Abbott Laboratories
13.2 Astellas Pharma, Inc.
13.3 Bayer AG
13.4 Enzon Pharmaceuticals, Inc.
13.5 GlaxoSmithKline plc
13.6 Glenmark
13.7 Merck & Co., Inc.
13.8 Novartis AG
13.9 Pfizer, Inc.
13.10 Sanofi
